近年来 T 细胞受体 (TCR) 细胞疗法因其为癌症和感染性疾病提供一系列可能性的治疗而获得广泛关注。由于γδ T细胞被视为对癌症免疫治疗颇有潜力的区域细胞,基于γδ T细胞的新型免疫疗法正在被大力开发。尽管TCR疗法在研发、生产及临床应用等领域已经取得重大进展,但 TCR细胞疗法的开发在功效及安全性方面仍然面临很多挑战。 MARS® 平台为优化和扩大 γδ T细胞的研发和生产提供了一种简单而又全新的方法和工具,可以帮助TCR 疗法最大化的发挥临床潜力。
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
We divide cookies into necessary cookies and third-party cookies that relate to functionality, technical issues and the collection of statistical and marketing data. No consent to third-party cookies allows you to continue using the website.
If you are looking for more information, we invite you to read our privacy policy.